All News

Anacaulase-bcdb improves current standard of care for deep partial thickness and/or full thickness thermal burns.

At the upcoming hearing, the committee will examine the impact of PBMs on access to healthcare and the Pharmacy Benefit Manager Transparency Act which was submitted by Sens. Maria Cantwell and Chuck Grassley.

After being FDA approved in 2021, tezepelumab (Tezspire) has been approved again for self-administration.

Sacituzumab govitecan significantly improved overall survival over the comparator chemotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer who had received prior treatment.

Your weekly roundup of the latest news from Drug Topics®.

After an on-field cardiac arrest, Hamlin partnered with the American Heart Association to spotlight the importance of CPR

Geographical data could potentially yield insight on racial and ethnic health disparities in the United States. An analysis of the large dataset could help identify any potential causes for observed inequities.

Adalimumab-atto was first approved by the FDA in 2016.

Sixteen states have banned a pharmacy benefit management practice that involves not counting the value of drug copay assistance from manufacturers toward patient deductibles.

Spending on specialty drugs fueled a 11% increase in Medicaid drug spending from 2020 to 2021, says Magellan's seventh annual Medicaid Pharmacy Trend Report.

Your weekly roundup of the latest news from Drug Topics®.

A new membership program, SmartRx, offers consumers savings on prescriptions, as well as office visits, eye care, vaccines and pet meds.

Rykindo is a bi-weekly long-acting risperidone injection to treat patients with schizophrenia and bipolar 1 in adults.

Your weekly roundup of the latest news from Drug Topics®.

This National Pharmacist Day, take the time to reflect on how pharmacists have stepped up during the pandemic.

Pharmacists can play an important role in patients’ wellness journeys.

Clarivate analysts have identified the treatments they forecast could deliver annual sales of more than $1 billion within 5 years. These include therapies for rare diseases, as well as HIV, Parkinson’s disease, Crohn’s disease, alopecia, and cancer.

Custom is one of the growing number of companies focusing on adherence. It changed its name from Pack4U last year.

Approval followed resubmission of data from the phase 3 CONFIRM trial to the agency.

Your weekly roundup of the latest news from Drug Topics®.

List prices of 450 medications have increased 5% overall at the beginning of 2023. More price hikes are expected.

A look at what’s to come in the January issue of Drug Topics®

Take a look back at our most popular women's health coverage for 2022.

Take a look back at our most popular news from December 2022.

Take a look back at the top 15 articles that we published in 2022.

Take a look back at our most popular dermatology coverage for 2022.

Take a look back at our most popular Total Pharmacy coverage for 2022.

Take a look back at our most popular pain management coverage for 2022.